Dublin, Feb. 10, 2021 (GLOBE NEWSWIRE) -- The "Anti-Viral Drug Therapy Global Market Opportunities and Strategies to 2030: COVID-19 Implications and Growth" report has been added to ResearchAndMarkets.com's offering.
This report provides strategists, marketers and senior management with the critical information they need to assess the global anti-viral drug therapy market.
The global anti-viral drug therapy market reached a value of nearly $46,456.4 million in 2019, having increased at a compound annual growth rate (CAGR) of 5.0% since 2015. The market is expected to grow from $46,456.4 million in 2019 to $ 61,571.9 million in 2020 at a rate of 32.5%. The growth is mainly due to the increase in number of COVID-19 cases. The market is then expected to grow at a CAGR of 8.3% from 2021 and reach $74,385.9 million in 2023. The market is expected to reach $ 87,230.5 million in 2025, and $ 130,125.3 million in 2030.
Reasons to Purchase
- Outperform competitors using accurate up to date demand-side dynamics information.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Identify growth segments for investment.
- Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
- Create regional and country strategies on the basis of local data and analysis.
- Stay abreast of the latest customer and market research findings
- Benchmark performance against key competitors.
- Develop strategies based on likely future developments.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Gain a global perspective on the development of the market.
The report covers the following chapters
- Executive Summary - The executive summary section of the report gives a brief overview and summary of the report
- Report Structure - This section gives the structure of the report and the information covered in the various sections.
- Introduction - The introduction section of the report gives brief introduction about segmentation by geography, segmentation by drug class, by application.
- Market Characteristics - The market characteristics section of the report defines and explains the anti-viral drug therapy market. This chapter also defines and describes goods and related services covered in the report.
- Trends And Strategies - This chapter describes the major trends shaping the global anti-viral drug therapy market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.
- Impact of COVID-19 - This section describes the impact of COVID-19 on the anti-viral drug therapy market.
- Global Market Size And Growth - This section contains the global historic (2015-2019) and forecast (2019-2023), (2023-2025), and (2025-2030) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional Analysis - This section contains the historic (2015-2019) and forecast (2019-2023), (2023-2025), and (2025-2030) market values and growth and market share comparison by region.
- Segmentation - This section contains the market values (2015-2030) and analysis for different segments.
- Regional Market Size and Growth - This section contains the region's market size (2019), historic (2015-2019) and forecast (2019-2023), (2023-2025), and (2025-2030) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, South America, Middle East and Africa and major countries within each region. The market overview sections of the report describe the current size of the market, background information, government initiatives, regulations, regulatory bodies, associations, corporate tax structure, investments, and major companies.
- Competitive Landscape - This section covers details on the competitive landscape of the global anti-viral drug therapy market, estimated market shares and company profiles for the leading players.
- Key Mergers And Acquisitions - This chapter gives the information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
- Future Outlook and Potential Analysis - This section includes market opportunities and strategies based on findings of the research. This section also gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
- Conclusions And Recommendations - This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for anti-viral drug therapy companies in terms of product offerings, geographic expansion, marketing strategies and target groups.
- Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report
The anti-viral drug therapy market is segmented by drug class into DNA (Nucleotide) polymerase inhibitors, protease inhibitors, reverse transcriptase inhibitors, neuraminidase inhibitors and others. Reverse transcriptase inhibitors market was the largest segment of the anti-viral drug therapy market segmented by drug class, accounting for 50.0% of the total in 2019. Also, it is expected to be the fastest-growing segment in the anti-viral drug therapy market segmented by drug class, at a CAGR of 20.0% during 2019-2023.
The anti-viral drug therapy market is also segmented by application into HIV, hepatitis, herpes, influenza and others. The HIV market was the largest segment of the anti-viral drug therapy market segmented by application, accounting for 34.1% of the total in 2019. Going forward, the influenza segment is expected to be the fastest-growing segment in the anti-viral drug therapy market segmented by application, at a CAGR of 14.5% during 2019-2023.
North America was the largest region in the global anti-viral drug therapy market, accounting for 50.6% of the total in 2019. It was followed by the Asia Pacific and Western Europe, and then the other regions. Going forward, the fastest-growing regions in the anti-viral drug therapy market will be the Asia Pacific and Africa, where growth will be at CAGRs of 14.7% and 13.8% respectively. These will be followed by the Middle East and North America, where the markets are expected to grow at CAGRs of 13.7% and 12.3% respectively.
The global anti-viral drug therapy market is highly concentrated, with a small number of global players in the market. The top ten competitors in the market made up to 76.53% of the total market in 2019. Major players in the market include Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, AbbVie Inc., and Merck & Co., Inc.
The top opportunities in the anti-viral drug therapy market segmented by drug class will arise in the reverse transcriptase inhibitors market segment, which will gain $24,880.4 million of global annual sales by 2023. The top opportunities in the anti-viral drug therapy market segmented by application will arise in the HIV segment, which will gain $ 10,038.8 million of global annual sales by 2023.
The anti-viral drug therapy market size will gain the most in India at $13,190.3 million. Market-trend-based strategies for the anti-viral drug therapy market include developing combination drugs, investing in strategic collaborations, leveraging 3D bioprinting to accelerate process of drug development. Player-adopted strategies in the anti-viral drug therapy market include expanding through strategic acquisitions and collaborations, and launching new drugs and focusing on the development of drugs against COVID-19.
Amidst the unprecedented outbreak of coronavirus, governments across the world are advising people to stay indoors and practice social distancing, to reduce the spread of the pandemic. This has decreased short-term potential growth opportunities for the anti-viral drug therapy industry. Lockdown halted manufacturing activities several countries owing to social distancing measures. However, an increasing number of COVID-19 cases across the world is positively affecting the anti-viral drugs market.
To take advantage of the opportunities, the publisher recommends the anti-viral drug therapy companies to focus on combination drug therapies, invest in 3D bioprinting technology, focus on R&D investments and research collaborations, focus on increasing production temporarily during the covid-19 pandemic, expand in emerging markets, leverage e-commerce to maximize reach and revenues, leverage online pharmacies, provide competitively priced offerings in low-income countries to reach new users, provide premium pricing for branded drugs, focus on increasing awareness on the importance of healthcare, advising asthmatics to use preventive medication to protect against covid-19, focus on educating the people on vaccines and focus on developing generics drugs.
Key Topics Covered:
1. Anti-Viral Drug Therapy Market Executive Summary
2. Table of Contents
3. List of Figures
4. List of Tables
5. Report Structure
6. Introduction
6.1.1. Segmentation By Geography
6.1.2. Segmentation By Drug Class
6.1.3. Segmentation By Application
7. Anti-Viral Drug Therapy Market Characteristics
7.1. Market Definition
7.2. Market Segmentation By Drug Class
7.2.1. DNA (Nucleotide) Polymerase Inhibitors
7.2.2. Reverse Transcriptase Inhibitors
7.2.3. Protease Inhibitors
7.2.4. Neuraminidase Inhibitors
7.2.5. Others
7.3. Market Segmentation By Application
7.3.1. HIV
7.3.2. Hepatitis
7.3.3. Herpes
7.3.4. Influenza
7.3.5. Others
8. Anti-Viral Drug Therapy Market Trends And Strategies
8.1. Combination Drug Therapy For Viral Diseases
8.2. Strategic Collaborations And Agreements
8.3. Global Research Initiatives And Funding
8.4. 3D Bioprinting Technology
8.5. Increasing Number Of Pipeline Studies And Drug Development
9. Impact Of COVID-19 On Anti-Viral Drug Therapy Market
9.1. Background
9.2. Drug Therapies
9.3. Antiviral Remdesivir Market Growth
10. Global Anti-Viral Drug Therapy Market Size And Growth
10.1. Market Size
10.2. Historic Market Growth, 2015 - 2019, Value ($ Million)
10.2.1. Drivers Of The Market 2015 - 2019
10.2.2. Restraints On The Market 2015 - 2019
10.3. Forecast Market Growth, 2019 - 2023, 2025F, 2030F Value ($ Million)
10.3.1. Drivers Of The Market 2019 - 2023
10.3.2. Restraints On The Market 2019 - 2023
11. Anti-Viral Drug Therapy Market, Regional And Country Analysis
11.1. Global Anti-Viral Drug Therapy Market, By Region, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
11.2. Global Anti-Viral Drug Therapy Market, By Country, Historic and Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Billion)
12. Global Anti-Viral Drug Therapy Market Segmentation
12.1. Global Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
12.2. Global Anti-Viral Drug Therapy Market, Segmentation By Application, Historic And Forecast, 2015 - 2019, 2023F, 2025F, 2030F, Value ($ Million)
Companies Mentioned
- Abbott Laboratories
- AbbVie Inc.
- Ache
- Alium
- Alkem Laboratories
- Apotex
- Ascedis Health
- Astellas Pharma
- AstraZeneca
- Atea Pharmaceuticals
- Aurobindo Pharma
- BioCryst Pharmaceuticals Inc.
- Biolab Farmaceutica
- BMS
- Boehringer Ingelheim
- Bristol-Myers-Squibb
- ChemRar Group
- China Meheco
- Chugai Pharmaceutical Co.
- Cipla Inc
- Cristalia
- CSPC Pharmaceutical
- Daewoong Pharmaceutical Co.,Ltd
- Daiichi Sankyo
- Divis Laboratories
- Dr. Reddy's Laboratories Ltd
- Eisai
- Emergent BioSolutions
- EMS Pharma
- Eurofarma
- Fosun Pharma
- Gilead Sciences Inc.
- GlaxoSmithKline plc
- Glenmark Pharmaceuticals
- Guangzhou Pharmaceutical Company Limited
- Gulf Pharmaceutical Industries (Julphar)
- Hanmi Pharmaceutical
- Harbin Pharmaceutical Group
- Hikma Pharmaceuticals
- Hypermarcas
- Intas Pharmaceuticals
- Jiangsu Hengrui Medicine Co., Ltd
- Johnson & Johnson
- Johnson & Johnson
- KYORIN Holdings, Inc.
- Libbs
- Lupin Limited
- Medical Appliances Corporation (SPIMACO)
- Medley
- Merck & Co., Inc.
- Mitsubishi Tanabe Pharma
- Mylan Laboratories
- Nichi-Iko Pharmaceutical Co., Ltd
- Novartis AG
- Novo Nordisk
- Otsuka Pharmaceutical
- Pfizer
- Pharmasyntez
- Pharmstandard
- R-Pharm
- Roche Holding AG
- Sanofi
- Saudi Pharmaceutical Industries
- Selva Therapeutics
- Servier
- Shanghai Acebright Pharmaceuticals Group Co., Ltd.
- Shanghai Pharmaceuticals
- Shionogi Co.Ltd.
- Sinopharm Group
- Strides Pharma
- Sumitomo Dainippon Pharma
- Sun Pharma
- Takeda Pharmaceutical Company
- Teuto Brasileiro
- Teva UK Limited
- Uniao Quimica
- Vectura Group
- Xian-Janssen Pharmaceutical Ltd
- Yangtze River Pharmaceutical Group
- Zydus Cadila
For more information about this report visit https://www.researchandmarkets.com/r/vnjpfw